KR960001724B1 - I,4-디하이드로피리딘, 이의 제조방법 및 이의 심장혈관 질환 치료제 - Google Patents

I,4-디하이드로피리딘, 이의 제조방법 및 이의 심장혈관 질환 치료제 Download PDF

Info

Publication number
KR960001724B1
KR960001724B1 KR1019880009867A KR880009867A KR960001724B1 KR 960001724 B1 KR960001724 B1 KR 960001724B1 KR 1019880009867 A KR1019880009867 A KR 1019880009867A KR 880009867 A KR880009867 A KR 880009867A KR 960001724 B1 KR960001724 B1 KR 960001724B1
Authority
KR
South Korea
Prior art keywords
methyl
ethyl
amino
methylenedioxyphenyl
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1019880009867A
Other languages
English (en)
Korean (ko)
Other versions
KR890003743A (ko
Inventor
페르낭데즈 토리자 칼로스
알바로 갈리아노 라모스 죠아뀐
Original Assignee
라보라토리오 드라그랑주
쟝 클라우드 가우빌
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 라보라토리오 드라그랑주, 쟝 클라우드 가우빌 filed Critical 라보라토리오 드라그랑주
Publication of KR890003743A publication Critical patent/KR890003743A/ko
Application granted granted Critical
Publication of KR960001724B1 publication Critical patent/KR960001724B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
KR1019880009867A 1987-08-03 1988-08-02 I,4-디하이드로피리딘, 이의 제조방법 및 이의 심장혈관 질환 치료제 Expired - Fee Related KR960001724B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP87401799.9 1987-08-03
EP87401799A EP0302980B1 (fr) 1987-08-03 1987-08-03 1,4-Dihydropyridines, leur procédé de préparation et leur application comme médicaments
EP87-401799.9 1987-08-03

Publications (2)

Publication Number Publication Date
KR890003743A KR890003743A (ko) 1989-04-17
KR960001724B1 true KR960001724B1 (ko) 1996-02-03

Family

ID=8198243

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019880009867A Expired - Fee Related KR960001724B1 (ko) 1987-08-03 1988-08-02 I,4-디하이드로피리딘, 이의 제조방법 및 이의 심장혈관 질환 치료제

Country Status (34)

Country Link
US (1) US4952592A (enExample)
EP (1) EP0302980B1 (enExample)
JP (1) JPH0733383B2 (enExample)
KR (1) KR960001724B1 (enExample)
CN (1) CN1038587C (enExample)
AT (1) ATE61588T1 (enExample)
BE (1) BE1001055A4 (enExample)
CA (2) CA1306261C (enExample)
CH (1) CH675999A5 (enExample)
CZ (1) CZ282077B6 (enExample)
DD (1) DD282008A5 (enExample)
DE (2) DE3768658D1 (enExample)
DK (1) DK430288A (enExample)
ES (1) ES2007543A6 (enExample)
FI (1) FI91406C (enExample)
GB (1) GB2208861B (enExample)
GR (2) GR880100507A (enExample)
HU (1) HU204523B (enExample)
IE (1) IE60358B1 (enExample)
IL (1) IL87321A (enExample)
IN (1) IN167550B (enExample)
IS (1) IS1549B (enExample)
IT (1) IT1235013B (enExample)
LU (1) LU87297A1 (enExample)
MA (1) MA21344A1 (enExample)
NO (1) NO170934C (enExample)
NZ (1) NZ225661A (enExample)
PH (1) PH25645A (enExample)
PT (1) PT88173B (enExample)
RU (1) RU2036922C1 (enExample)
SK (1) SK278775B6 (enExample)
TN (1) TNSN88081A1 (enExample)
YU (1) YU46547B (enExample)
ZA (1) ZA885684B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5242933A (en) * 1990-07-10 1993-09-07 Adir Et Compagnie Piperidine, tetrahydropyridine and pyrrolidine compounds
US5942516A (en) * 1995-08-02 1999-08-24 Elliott; John Duncan Endothelin receptor antagonists
RU2168987C2 (ru) * 1997-04-15 2001-06-20 Санкт-Петербургская Государственная Химико-Фармацевтическая Академия Гипотензивное средство
RU2155036C2 (ru) * 1998-11-11 2000-08-27 Азад Зияд Оглы Абышев Средство для лечения ишемической болезни сердца
IT1304513B1 (it) * 1998-12-30 2001-03-19 Endura Spa Processo per la sintesi di 5-(alfa-idrossialchil)benzo(1,3)diossoli.
DE60128683T2 (de) * 2000-04-11 2008-01-24 Sankyo Co., Ltd. Stabilisierte pharmazeutische zusammenstellungen die den calziumkanalblocker azelnidipine enthalten
RU2187303C2 (ru) * 2000-10-12 2002-08-20 Азад Зияд Оглы Абышев Способ получения таблеток диуманкала - forte по 0,01 г
CN1681495B (zh) 2002-08-19 2010-05-12 辉瑞产品公司 用于治疗过度增生性疾病的组合物
CA2574958A1 (en) * 2004-07-26 2006-02-09 Cotherix, Inc. Treatment of pulmonary hypertension by inhaled iloprost with a microparticle formulation
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
EP2351569B1 (en) 2005-10-26 2012-08-22 Asahi Kasei Pharma Corporation Fasudil in combination therapies for the treatment of pulmonary arterial hypertension
JP2009513660A (ja) * 2005-10-26 2009-04-02 旭化成ファーマ株式会社 肺動脈性高血圧の治療用併用療法におけるファスジル
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
TW200736245A (en) * 2005-11-29 2007-10-01 Sankyo Co Acid addition salts of optically active dihydropyridine derivatives
TW200806648A (en) * 2005-11-29 2008-02-01 Sankyo Co Acid addition salts of dihydropyridine derivatives
US7919506B2 (en) 2006-03-10 2011-04-05 Pfizer Inc. Dibenzyl amine compounds and derivatives
US8404896B2 (en) 2006-12-01 2013-03-26 Bristol-Myers Squibb Company N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as CETP inhibitors for the treatment of atherosclerosis and cardiovascular diseases
WO2012037665A1 (en) 2010-09-24 2012-03-29 Oral Delivery Technology Ltd. Nitric oxide releasing amino acid ester for treatment of pulmonary hypertension and other respiratory conditions
BR112015026513A2 (pt) 2013-04-17 2017-07-25 Pfizer derivados de n-piperidin-3-ilbenzamida para tratar as doenças cardiovasculares
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
RS66416B1 (sr) 2019-01-18 2025-02-28 Astrazeneca Ab 6'-[[(1s,3s)-3-[[5-(difluorometoksi)-2-pirimidinil]amino]ciklopentil]amino][1(2h),3'-bipiridin]-2-on kao inhibitor pcsk9 i metode njegove primene

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3441648A (en) * 1967-02-07 1969-04-29 Smithkline Corp Compositions and methods for lowering blood pressure with 1,4-dihydropyridines
US4031104A (en) * 1972-04-18 1977-06-21 Bayer Aktiengesellschaft 1,4-Dihydropyridine carboxylic acid esters
JPS5978186A (ja) * 1982-10-27 1984-05-04 Yoshitomi Pharmaceut Ind Ltd １，４−ジヒドロピリジン−３，５−ジカルボン酸エステル誘導体
IE57810B1 (en) * 1984-03-27 1993-04-21 Delagrange Lab 1,4-dihydropyridine derivatives,their preparation and their use
ES531033A0 (es) * 1984-03-27 1985-09-01 Inst Investigacion Desarrollo Un procedimiento para la preparacion de nuevas 1,4-dihidropirinas-4-(polioxialquilfenil)-sustituidas
JPH068294B2 (ja) * 1985-02-26 1994-02-02 富山化学工業株式会社 新規な１，４−ジヒドロピリジン誘導体およびその塩
EP0174131A3 (en) * 1984-09-01 1989-06-07 FISONS plc Dihydropyridines, processes and intermediates for their production, and pharmaceutical formulations containing them
JPH01207267A (ja) * 1987-03-05 1989-08-21 Yamanouchi Pharmaceut Co Ltd ピリジン誘導体及び該化合物を含有する肝疾患治療剤

Also Published As

Publication number Publication date
KR890003743A (ko) 1989-04-17
IL87321A (en) 1993-04-04
FI91406B (fi) 1994-03-15
IS3378A7 (is) 1989-02-04
JPH0733383B2 (ja) 1995-04-12
PT88173B (pt) 1995-03-01
EP0302980B1 (fr) 1991-03-13
FI883603A0 (fi) 1988-08-01
RU2036922C1 (ru) 1995-06-09
DE3825962A1 (de) 1989-02-16
IT8848259A0 (it) 1988-08-02
CA1306262C (fr) 1992-08-11
PH25645A (en) 1991-08-21
GR880100507A (el) 1989-05-25
DK430288D0 (da) 1988-08-02
IE882364L (en) 1989-02-03
AU606441B2 (en) 1991-02-07
FI883603A7 (fi) 1989-02-04
ZA885684B (en) 1989-04-26
DK430288A (da) 1989-02-03
GB2208861B (en) 1991-07-17
JPH01294675A (ja) 1989-11-28
IS1549B (is) 1994-06-08
GB8818356D0 (en) 1988-09-07
IN167550B (enExample) 1990-11-10
YU147088A (en) 1990-04-30
ES2007543A6 (es) 1989-06-16
EP0302980A1 (fr) 1989-02-15
AU2033088A (en) 1989-02-09
US4952592A (en) 1990-08-28
GB2208861A (en) 1989-04-19
CZ282077B6 (cs) 1997-05-14
IE60358B1 (en) 1994-06-29
NO883406L (no) 1989-02-06
FI91406C (fi) 1994-06-27
CN1031531A (zh) 1989-03-08
PT88173A (pt) 1989-06-30
HU204523B (en) 1992-01-28
NZ225661A (en) 1990-08-28
GR3001984T3 (en) 1992-11-23
IT1235013B (it) 1992-06-16
BE1001055A4 (fr) 1989-06-20
YU46547B (sh) 1993-11-16
NO170934B (no) 1992-09-21
SK541388A3 (en) 1998-02-04
CN1038587C (zh) 1998-06-03
CA1306261C (fr) 1992-08-11
TNSN88081A1 (fr) 1990-07-10
CH675999A5 (en) 1990-11-30
ATE61588T1 (de) 1991-03-15
SK278775B6 (sk) 1998-02-04
CZ541388A3 (en) 1997-01-15
HUT54142A (en) 1991-01-28
LU87297A1 (fr) 1989-02-02
MA21344A1 (fr) 1989-04-01
IL87321A0 (en) 1989-01-31
NO170934C (no) 1992-12-30
NO883406D0 (no) 1988-08-01
DD282008A5 (de) 1990-08-29
DE3768658D1 (de) 1991-04-18

Similar Documents

Publication Publication Date Title
KR960001724B1 (ko) I,4-디하이드로피리딘, 이의 제조방법 및 이의 심장혈관 질환 치료제
CA1205480A (en) Dihydropyridine anti-ischaemic and antihypertensive agents, processes for their production, and pharmaceutical compositions containing them
US4220649A (en) 1,4-Dihydropyridine-3,5-dicarboxylic acid ester derivatives
KR880002357B1 (ko) 디히드로피리딘 유도체의 제조방법
CA1239401A (en) Derivatives of dihydropyridine-3,5-dicarboxylate and pyran-3,5-dicarboxylate
FI90343C (fi) Menetelmä korkeaa verenpainetta alentavien ja rytmihäiriöitä vastustavien trans-2,2-dimetyylikroman-3-olijohdannaisten valmistamiseksi
JPH0542431B2 (enExample)
NZ194805A (en) 1,4-dihydropyridine derivatives and pharmaceutical compositions
EP0296316A1 (de) 1,4-Dihydropyridin-Enantiomere
JPH01151555A (ja) フルオロメトキシフエニルジヒドロピリジン類
JPS6256474A (ja) ジヒドロピリジン−２−ヒドロキシアミン類
IL46593A (en) 2-amino-6-dialkylamino-dihydropyridines their production and pharmaceutical compositions containing them
CA2080864A1 (en) Aryl-quinolyl-substituted 1,4-dihydropyridine-dicarboxylic acid derivatives, processes for their preparation and their use in drugs
EP0124777B1 (en) 1,4-dihydropyridine derivatives
JPS62270528A (ja) 血圧降下剤
JPS5976083A (ja) ジヒドロピリジン類
US4732898A (en) 2-(2-aryl-2-oxoalkylidene) analogs of-3,5-pyridinedicarboxylic acid dialkyl esters useful for treatment of cardiovascular disorders
JPH0526777B2 (enExample)
EP0463407B1 (en) Use of dihydropyridins in cardiotonic pharmaceutical compositions
JPS61251661A (ja) １，４−ジヒドロピリジン誘導体
JPS62169796A (ja) ジヒドロピリジン−５−ホスホン酸エステル類
JPS6163689A (ja) ピリジン誘導体
JPS6092266A (ja) １，４−ジヒドロピリジン−３，５−ジカルボン酸ジエステル誘導体，その製造法及びそれを有効成分とする薬剤

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

G160 Decision to publish patent application
PG1605 Publication of application before grant of patent

St.27 status event code: A-2-2-Q10-Q13-nap-PG1605

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

FPAY Annual fee payment

Payment date: 19990112

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20000204

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20000204

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000